OXFD - Oxford Immunotec's COVID-19 test to be used Valneva's COVID-19 vaccine candidate trial

Oxford Immunotec ([[OXFD]] -1.0%) has collaborated with Valneva, wherein, the company will perform T cell testing on participants receiving Valneva's inactivated whole-virus COVID-19 vaccine candidate (VLA2001) with the research use only T-SPOT Discovery SARS-CoV-2 test.The VLA2001-201 study is a Phase 1/2 study designed to evaluate the safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 virus vaccine candidate in healthy subjects, in Europe.The company's T-SPOT Discovery SARS-CoV-2 test will assess if the vaccination induces a T cell response in study subjects.

For further details see:

Oxford Immunotec's COVID-19 test to be used Valneva’s COVID-19 vaccine candidate trial